Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712068 | 0.89 | RAB9A (0.67) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL17468789 | 0.83 | RAB9A (0.61) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL12767148 | 0.80 | HTT (0.83) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL17482180 | 0.80 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL27926814 | 0.79 | SMN1; SMN2 (0.66) | HTTSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL7694906 | 0.78 | SMN1; SMN2 (0.70) | HTTSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL3661523 | 0.78 | SMN1; SMN2 (0.54) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL4138642 | 0.76 | HTT (0.68) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL20626725 | 0.75 | MAPT (0.55) | HTTSMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL17482198 | 0.75 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2RAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5274091-A | ADMPT and its synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1993-12-28 | — | — | US | claimed |
| US-10174064-B2 | Photoactive energetic materials | TRIAD NATIONAL SECURITY, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2220176-B1 | SOL-GEL COATING COMPOSITIONS AND THEIR PROCESS OF PREPARATION | DUBLIN INSTITUTE OF TECH INTELLECTUAL PROPERTY LTD (IE) | 2018-09-19 | — | — | EP | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20100330380-A1 | Organosilane Coating Compositions and Use Thereof | DUBLIN CITY UNIVERSITY (IE) | 2010-12-30 | — | — | US | disclosed |
| US-20100330380-A1 | Organosilane Coating Compositions and Use Thereof | DUBLIN CITY UNIVERSITY (IE) | 2010-12-30 | — | — | US | disclosed |
| US-20100330380-A1 | Organosilane Coating Compositions and Use Thereof | DUBLIN CITY UNIVERSITY (IE) | 2010-12-30 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| US-5281706-A | Synthesis of 3,6-diamino-1,2,4,5-tetrazine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1994-01-25 | — | — | US | disclosed |
| US-5274091-A | ADMPT and its synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5274091-A | ADMPT and its synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174064-B2 | Photoactive energetic materials | NOX5, TRPM5, MT-ND5 | HTT 1534/4885SMN1; SMN2 4635/4885RAB9A 4208/4885 |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | NOX5, TRPM5, MT-ND5 | HTT 1534/4885SMN1; SMN2 4635/4885RAB9A 4208/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | HTT 2080/4885SMN1; SMN2 2829/4885RAB9A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.